Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCelLBxHealth plc

CelLBxHealth plc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.6 GBX 0.00(0%)
Last update at 2026-10-27T16:22:00Z
VOLUME
624929
Market Cap
18.50M

Momentum Score

…

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.58
Low
0.60
High
52 Week Price Range
0.85
Low
11.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.60
Dividend Yield
-
Revenue TTM
2.62M
Revenue Per Share
0.01
Gross Profit TTM
0.82M
Debt / Equity
-
ROE
-87.18%
Net Debt
-
ROCE
-69.70%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.03M -21.63M -24.44M -17.36M
Net income -14.22M -20.13M -21.69M -15.01M
Selling general administrative 0.46M 0.38M 0.56M 0.34M
Gross profit 1.78M 1.53M 0.61M 0.71M
Reconciled depreciation 1.70M 2.31M 2.84M 1.49M
Operating income -15.47M -20.46M -26.11M -17.33M
Interest expense 0.31M 0.33M 0.35M 0.16M
Tax provision -0.80M -1.50M -2.75M -2.35M
Interest income 0.40M 0.46M 0.14M 0.03M
Net interest income 0.09M 0.14M -0.22M -0.13M
Total revenue 2.86M 2.19M 1.04M 1.01M
Total operating expenses 18.34M 22.64M 27.15M 18.34M
Cost of revenue 1.08M 0.66M 0.43M 0.30M
Net income from continuing ops -14.22M -20.13M -21.69M -15.01M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25.46M 31.18M 49.87M 47.31M
Intangible assets 0.44M 0.53M 0.56M 1.37M
Total liab 7.02M 8.24M 9.80M 6.99M
Total stockholder equity 18.44M 22.94M 40.06M 40.33M
Capital stock 32.26M 26.06M 26.06M 23.51M
Retained earnings -133.15M -122.33M -103.70M -83.81M
Good will 2.21M 2.21M 2.21M 2.21M
Cash 10.43M 16.22M 31.90M 31.84M
Total current liabilities 3.26M 3.94M 5.25M 4.91M
Total current assets 16.41M 21.22M 38.63M 39.37M
Net receivables 0.77M 0.73M 0.32M 0.20M
Inventory 1.58M 1.68M 2.06M 1.75M
Accounts payable 0.69M 1.06M 1.50M 1.12M
Non current assets total 9.05M 9.97M 11.24M 7.95M
Capital lease obligations 4.21M 4.55M 5.00M 2.34M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.05M -0.20M -1.75M 14.77M
Net income -14.22M -20.13M -21.69M -15.01M
Change in cash -5.83M -15.79M 0.29M 19.75M
Begin period cash flow 16.22M 31.90M 31.84M 12.08M
End period cash flow 10.43M 16.22M 31.90M 31.84M
Total cash from operating activities -13.45M -14.46M -16.05M -14.01M
Issuance of capital stock 8.63M 0.01M 19.05M 19.69M
Depreciation 1.70M 2.31M 2.84M 1.49M
Change to inventory 0.15M 0.09M -0.58M -1.01M
Capital expenditures 0.44M 0.66M 1.89M 1.79M
Change in working capital -1.13M -1.03M -1.61M 0.61M
Stock based compensation 1.45M 1.89M 4.39M 1.32M
Other non cash items -0.07M -0.13M 0.23M 0.13M
Free cash flow -13.89M -15.12M -17.94M -15.80M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CLBX
CelLBxHealth plc		 -
-%		 0.60 - - 7.05 1.50 6.07 -1.62
IDHC
Integrated Diagnostics Holdings PLC		 -
-%		 0.48 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 -
-%		 5.55 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -
-%		 9.00 - 53.19 2.19 3.19 1.81 -0.25
GDR
genedrive plc		 0.03
2.44%		 1.05 - 12.38 12.99 10.61 16.54 -6.05

Profile*

CelLBxHealth plc

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Surrey Research Park, Guildford, United Kingdom, GU2 7AF

44 14 8334 3434

https://cellbxhealth.com

119

Name Title Year Born
Ms. Sinéad Eithne Armstrong Finance Director & Secretary NA
Ms. Michelle Munson Chief of Staff NA
Dr. Lauren Arthy-Miles ESG Lead NA
Dr. Cristina Ciccioli Head of Assay Development NA
Mr. Peter Michael Collins CEO & Director 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…